2nd IBDHorizons Advanced Practice Provider (APP): Multiplatform Symposium
We are pleased to announce the IBDHorizons APP Symposium is back for the 2nd year.
Medical providers attend IBDHorizons Symposiums at no cost.
Course Information
Conference:
- 1 Day – Novel multiplatform in-person & virtual attendance covering the Pacific Northwest region with an estimated 200 attendees.
- In-person attendance will be limited to meet the highest safety standards. A complete virtual conference platform will be offered exclusively if in-person attendance cannot be safely conducted.
- Format will include a series of IBD-focused presentations, panel discussions, and case studies with dynamic attendee participation using audience interactive technology.
Intended Audience
This activity was developed for nurse practitioners, physician assistants, gastroenterology registered nurses, clinical nurse specialists, pharmacists, dietitians, medical assistants, physicians, and family practitioners involved in the care of patients with IBD.
Learning Objectives
At the conclusion of this learning activity, participants will do the following:
- Outline the goals of IBD care and incorporate the latest concepts, including treat-to-target in IBD clinical practice to maximize patient outcomes.
- Appraise the available non-invasive testing (including blood, stool tests, and imaging modalities) to evaluate for disease activity in IBD and interpret these studies relative to other objective markers of disease such as endoscopy.
- Assess current knowledge on infection risk in IBD, including COVID-19, and the implications on managing IBD patients, especially during the current pandemic, including the risk of complications, interrupting therapy, and vaccination guidelines.
- Review the common dermatologic extraintestinal manifestations in IBD (related to disease, therapy, or complications) and apply a practical approach to screen and intervene as needed.
- Review the causes of active symptoms in IBD patients in clinical remission and apply a practical approach to diagnose and manage GI symptoms in the absence of active inflammation.
- Appraise the available telemedicine models of health care delivery with their advantages and limitations and apply this knowledge to enhance equitable IBD patient care access and outcomes, especially for underserved populations.
- Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
- Discuss the newly approved and soon-to-be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.
-
Accreditation:
Accreditation and Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Annenberg Center for Health Sciences at Eisenhower and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Physicians
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.A maximum of 6 contact hours, including 1.25 hours of pharmacology, may be earned for successful completion of this activity.
Pharmacists
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-21-105-L01-P. This program is designated for up to 6 contact hours (0.6 CEUs) of continuing pharmacy education credit.Physician Assistants
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 6 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/16/2021 to 10/16/2021. AAPA reference number: CME-203725.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgement in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited educational activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Disclosure of Conflict of Interest
Faculty
Anita Afzali, MD, MPH
Consultant for AbbVie, BMS/Celgene, Gilead, Janssen, Pfizer, Takeda; and a speaker for AbbVie, Janssen, Pfizer, TakedaKarlee Ausk, MD
No relevant commercial relationships to discloseMitra Barahimi, MD
Advisory board for JanssenSarah Chou, MPAS
No relevant commercial relationships to discloseJeff Jacobs, MD
No relevant commercial relationships to discloseScott D. Lee, MD
Consultant for AbbVie, Arena, BMS, Eli Lilly, Janssen, UCBDavid Suskind, MD
Patent royalties from MicrobiomX LLC; and stockholder for Nimal Health LLCGhassan Wahbeh, MD
Consultant and Data and Safety Monitoring Board for AbbVie; and receives research support from AbbVie, Janssen, TakedaIBDHorizons
All staff at IBDHorizons have no relevant commercial relationships to disclose.Annenberg Center for Health Sciences at Eisenhower
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.Nurse Reviewers
Heather Jimenez, FNP-C, has nothing to disclose.
Amber Lea Lambert, MSN, FNP-C, DNP, has nothing to disclose.This activity is supported by educational grants from Ferring Pharmaceuticals Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; and Takeda Pharmaceuticals USA, Inc.
IBDHorizons Privacy Policy
https:/ibdhorizons.org/privacy-policyAnnenberg Center for Health Sciences Privacy Policy
Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php
Hourly Schedule
Morning Session
- 8:15 - 9:00
- Goals of Therapy in IBD: Where are we today?
- 10 Minute Presentation followed by a Panel Discussion with 2 other speakers.
-
Speakers:
Ghassan Wahbeh-- MD
- 9:00 - 9:45
- Monitoring Disease Activity: Why & How
-
Speakers:
Karlee Ausk-- MD
- 9:45 - 10:15
- Break
- 10:15 - 11:00
- Family Planning, Pregnancy, and IBD Management
-
Speakers:
Sarah Chou-- PA-C
- 11:45 - 12:30
- Lunch
- 12:30 - 13:15
- Infection Risk in IBD: Focus on COVID-19
-
Speakers:
Jeffrey Jacobs-- MD
- 13:15 - 14:00
- Clinical Models of IBD Care: Eye on Telemedicine
-
Speakers:
Mitra Barahimi-- MD
- 14:00 - 14:45
- Approach to the Symptomatic IBD Patient in Endoscopic
-
Speakers:
David Suskind-- MD
- 14:45 - 15:20
- Skin Manifestations of IBD and IBD-therapy
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
Date
Time
Location
Location 2
- IBDH Virtual Platform
Speakers
-
Anita Afzali, MD, MPH, MHCMProfessor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
-
David Suskind, MDDirector, Quality Improvement; Co-chair, Nutrition Subcommittee, Professor of Pediatrics
-
Ghassan Wahbeh, MDDirector of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children’s.
Dr. Wahbeh’s research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children’s Hospital.
Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.
He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
-
Jeffrey Jacobs, MDGastroenterologist at University of Washington
Jeffrey Jacobs, MD, is a gastroenterologist and specializes in the care of patients with inflammatory bowel diseases (IBD).
Dr. Jacobs believes in a patient-centered and team based approach to medical care, while using the most up-to-date research to get the best outcome for his patients. He realizes that each patient is different, and a tailored approach is critical to the successful care of his patients.
Dr. Jacobs’ primary clinical interest is in the care of patients with inflammatory bowel disease.
Dr. Jacobs enjoys playing with his dog at the park, trying out new cooking and baking recipes with his wife, traveling, reading books about history, and watching football (Go Hawks!).
-
Karlee Ausk, MDAssociate Director/Lead MD, Swedish IBD Center
Dr. Ausk attended medical school at the University of Washington, where she also completed Internal Medicine residency, chief residency, and fellowship in Gastroenterology and Hepatology. She practices general gastroenterology and hepatology with a particular interest in inflammatory bowel disease (IBD) and colorectal cancer screening. She believes that healthcare providers have the privilege of accompanying patients and their families through the often stressful times brought on by an illness. She strives to guide patients in making healthcare decisions considering the best evidence available tailored to their individual story.
-
Mitra Barahimi, MDAssistant Professor of Medicine at University of Washington
Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel diseases (IBD). She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington.
In her clinical practice, Dr. Barahimi exclusively cares for patients with IBD. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation (CCF), American Gastroenterology Association (AGA), American College of Gastroenterology (ACG), and American Society of Gastrointestinal Endoscopy (ASGE).
-
Sarah Chou, PA-CPhysician Assistant
Sarah Chou is a Gastroenterology Physician Assistant and Teaching Associate at the University of Washington.
Hourly Schedule
Morning Session
- 8:15 - 9:00
- Goals of Therapy in IBD: Where are we today?
- 10 Minute Presentation followed by a Panel Discussion with 2 other speakers.
-
Speakers:
Ghassan Wahbeh-- MD
- 9:00 - 9:45
- Monitoring Disease Activity: Why & How
-
Speakers:
Karlee Ausk-- MD
- 9:45 - 10:15
- Break
- 10:15 - 11:00
- Family Planning, Pregnancy, and IBD Management
-
Speakers:
Sarah Chou-- PA-C
- 11:45 - 12:30
- Lunch
- 12:30 - 13:15
- Infection Risk in IBD: Focus on COVID-19
-
Speakers:
Jeffrey Jacobs-- MD
- 13:15 - 14:00
- Clinical Models of IBD Care: Eye on Telemedicine
-
Speakers:
Mitra Barahimi-- MD
- 14:00 - 14:45
- Approach to the Symptomatic IBD Patient in Endoscopic
-
Speakers:
David Suskind-- MD
- 14:45 - 15:20
- Skin Manifestations of IBD and IBD-therapy
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
-
Accreditation:
Accreditation and Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Annenberg Center for Health Sciences at Eisenhower and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Physicians
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.A maximum of 6 contact hours, including 1.25 hours of pharmacology, may be earned for successful completion of this activity.
Pharmacists
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-21-105-L01-P. This program is designated for up to 6 contact hours (0.6 CEUs) of continuing pharmacy education credit.Physician Assistants
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 6 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/16/2021 to 10/16/2021. AAPA reference number: CME-203725.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgement in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited educational activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Disclosure of Conflict of Interest
Faculty
Anita Afzali, MD, MPH
Consultant for AbbVie, BMS/Celgene, Gilead, Janssen, Pfizer, Takeda; and a speaker for AbbVie, Janssen, Pfizer, TakedaKarlee Ausk, MD
No relevant commercial relationships to discloseMitra Barahimi, MD
Advisory board for JanssenSarah Chou, MPAS
No relevant commercial relationships to discloseJeff Jacobs, MD
No relevant commercial relationships to discloseScott D. Lee, MD
Consultant for AbbVie, Arena, BMS, Eli Lilly, Janssen, UCBDavid Suskind, MD
Patent royalties from MicrobiomX LLC; and stockholder for Nimal Health LLCGhassan Wahbeh, MD
Consultant and Data and Safety Monitoring Board for AbbVie; and receives research support from AbbVie, Janssen, TakedaIBDHorizons
All staff at IBDHorizons have no relevant commercial relationships to disclose.Annenberg Center for Health Sciences at Eisenhower
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.Nurse Reviewers
Heather Jimenez, FNP-C, has nothing to disclose.
Amber Lea Lambert, MSN, FNP-C, DNP, has nothing to disclose.This activity is supported by educational grants from Ferring Pharmaceuticals Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; and Takeda Pharmaceuticals USA, Inc.
IBDHorizons Privacy Policy
https:/ibdhorizons.org/privacy-policyAnnenberg Center for Health Sciences Privacy Policy
Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php